Luciano Costa, MD, PhD, Discusses the Safety Profile of Dara-KRd From the MASTER Trial in Newly Diagnosed Multiple Myeloma

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the most common adverse effects experienced from the quadruplet drug treatment for patients with multiple myeloma.

At the 2021 International Myeloma Conference, CancerNetwork® spoke with Luciano Costa, MD, PhD, of O’Neal Comprehensive Cancer Center, about the safety profile of daratumumab (Darzalex), carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Dara-KRd) as seen in the phase 2 MASTER trial (NCT03224507).


I wouldn’t say there were any new safety findings, but what we saw was toxicities that have been seen in prior studies with any one of the drugs [ that were] utilized. The most common [adverse] effects [AEs] or the most common severe AEs in [this trial] were pneumonia that we saw in 8 of 123 patients, and pulmonary thromboembolism that we saw in 3 patients of the 123. The infection and pulmonary thromboembolism, and cardiovascular events have been linked to the different elements of this combination. We had 3 deaths during treatment—1 was a sudden death on the second week of induction. It’s difficult to say if it was treatment or the disease burden or something completely unrelated. One [death] was 2 months after transplant, before the patient started consolidation and it was also a sudden death. Finally, 1 patient [died from] pneumonia 6 months after transplant. Each one of those [deaths], is in itself a tragedy, but it’s difficult to do attribution and even to say it is higher than expected, given the non-randomized nature of this study.


Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment duration and cessation in newly diagnosed multiple myeloma (NDMM). Paper presented at: 18th International Myeloma Workshop; September 8-11, 2021; Vienna, Austria. Accessed September 11, 2021.

Related Videos
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
Experts on multiple myeloma
Experts on multiple myeloma
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Experts on multiple myeloma
Experts on multiple myeloma
Related Content